CytoCore's CEO Interviewed by Wall Street Reporter.

CHICAGO -- CytoCore, Inc. (OTCBB: MCDG) announced that CEO David Weissberg was interviewed by The Wall Street Reporter this past week. Dr. Weissberg discussed CytoCore's market focus and strategy for success, and provided a detailed description of The InPath(TM) System, a cervical cancer screening and treatment system developed by Dr. George Gorodeski. The interview can be found and heard on http://www.wallstreetreporter.com as well as the Company's web site, http://www.molecular-dx.com.

"I am pleased to have had the opportunity to speak with The Wall Street Reporter about CytoCore and our services," said Dr. Weissberg. "Our products have the potential to equip physicians all over the world with the capability of identifying and treating cervical and uterine cancers in its early stages. We are eager to get the word out about this valuable new process."

About CytoCore, Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.